Join
Live feed
·
PRReleasevia Quantisnow
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

ByQuantisnow·Wall Street's wire, on your screen.
VRCA· Verrica Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRCA (Verrica Pharmaceuticals Inc.) and more on Quantisnow.